Myovant Sciences Ltd. Common Shares (MYOV) News
Filter MYOV News Items
MYOV News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest MYOV News From Around the Web
Below are the latest news stories about MYOVANT SCIENCES LTD that investors may wish to consider to help them evaluate MYOV as an investment opportunity.
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue EstimatesMyovant Sciences (MYOV) delivered earnings and revenue surprises of -5.36% and 3.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? |
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue of $61.4 millionNet product revenue from U.S. sales of ORGOVYX® of $48.7 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 13% and cumulative patients estimated at 26,000 through December 2022Net product revenue from U.S. sales of MYFEMBREE® of $10.5 million in third fiscal quarter 2022, with sequential quarterly demand volume growth of 49% and cumulative patients estima |
Lynn Seely steps into top role at cancer-fighting company Lyell ImmunopharmaSeely steps into the top operational roles at a company where outgoing president and CEO Liz Homans guided two cancer cell therapies into the clinic. |
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08BASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a biopharmaceutical company that aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy, today announced that it approved equity awards for 18 new employees with a grant date of November 15, 2022 pursuant to Myovant’s 2020 Inducement Plan. The equity awards were granted to the employees joining Myovant in accordance with NYSE’s Listed Comp |
Myovant Sciences Appoints Ann Tomlin as Senior Vice President of Human ResourcesBASEL, Switzerland, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV) today announced the appointment of Ann Tomlin as Senior Vice President of Human Resources. Beginning November 28, Ms. Tomlin will be responsible for developing talent solutions and human resources strategies across Myovant’s global functions. She will serve as a member of the Executive Committee and will report to David Marek, Myovant’s Chief Executive Officer. Ms. Tomlin has over 25 years of human resources expe |
Myovant Sciences (MYOV) Reports Q2 Loss, Tops Revenue EstimatesMyovant Sciences (MYOV) delivered earnings and revenue surprises of 4.08% and 13.94%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Myovant Sciences Announces Corporate Updates and Financial Results for Second Fiscal Quarter 2022On October 23, 2022, Sumitovant Biopharma Ltd. (Sumitovant), in conjunction with parent company Sumitomo Pharma Co., Ltd. (Sumitomo Pharma), and Myovant Sciences (Myovant) announced that they have entered into a definitive agreement pursuant to which Sumitovant will acquire all outstanding shares of Myovant not already owned by Sumitovant for $27.00 per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis, and a total company value of $2.9 billion |
Myovant Sciences Accepts Slightly Higher Takeover OfferThe drug developer finally agreed to a takeover offer from its majority shareholder after rejecting advances earlier this month. |
Myovant (MYOV) Stock Rising on Acquisition NewsMyovant Sciences Ltd. (MYOV) has risen more than 8% in pre-market trading, thanks to the news about its acquisition by Sumitomo Unit. Sumitomo, a subsidiary of Sumitomo Pharma Co., had already owned 52% of Myovant. Now, it offered $27 a share in cash for the rest of Myovant. Myovant stock has 4 Buy and 1 Hold ratings. It has risen nearly 50% year-to-date. |
MYOV Stock Pops as Sumitomo Agrees to Buy Myovant SciencesAcquisition announcements can cause explosive share-price moves, and MYOV stock is spiking in the wake of a big-dollar buyout announcement. |